Navigation Links
Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
Date:9/24/2010

SAN DIEGO, Sept. 24 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. announced today the initiation of a Phase I clinical trial of their first-in-class, oral CK2 inhibitor CX-4945 in patients with multiple myeloma. Cylene also announced the simultaneous closing of a $12 million financing with participation from existing investors including Sanderling Ventures, HBM BioVentures (Cayman) Ltd., Novartis BioVenture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments Ltd. Proceeds from the financing will be used to expand the human clinical trials program for CX-4945, including the Phase I trial in patients with multiple myeloma and a series of randomized Phase II trials.

The multi-center Phase I study with CX-4945 will be conducted in patients with relapsed or refractory multiple myeloma. The primary objectives of the study are to determine the safety, tolerance and pharmacokinetic (PK) properties of CX-4945 in multiple myeloma patients and to select the appropriate dose for Phase II trials. Secondary objectives are to investigate the pharmacodynamic (PD) activity of CX-4945 using mechanism and tumor-related PD biomarkers that have been validated in both preclinical and clinical studies. In preclinical studies with multiple myeloma cell lines, CX-4945 inhibited critical CK2-mediated events including key signaling pathways and mediators (PI3K/Akt, NFkB, IL-6) that are known to drive the proliferation of multiple myeloma. These findings, coupled with the need for new agents that target molecular pathways shared by all subtypes of multiple myeloma, highlight CX-4945 as a promising therapeutic agent for multiple myeloma.

A separate Phase I clinical trial in patients with solid tumors evaluating CX-4945 as an orally administered single agent has already established favorable pharmacokinetic and safety profiles. Measurement of mechanism and tumor-related biomarkers in patients established that CX-4945 hits the CK2 targ
'/>"/>

SOURCE Cylene Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
2. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
7. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
8. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
9. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
10. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
11. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2015)... Join us for a webinar at 12 ... Times using the Transcreener® ADP Assay , Register ... increasingly being incorporated into lead development efforts because longer ... increased therapeutic window and reduced side effects. Though ... such surface plasmon resonance, conjugation of drugs can affect ...
(Date:4/24/2015)... Top student social innovators from the ... universities, including UCSD and SDSU, will pitch their impact ... national and nonprofit companies for an opportunity to win ... Social Innovation Challenge 2015 . , The 2015 Social ... addressing a diverse range of issues including poverty, education, ...
(Date:4/24/2015)... AZ (PRWEB) April 24, 2015 The ... State University (ASU) have entered into an agreement to ... A memorandum of agreement signed by the universities will ... student success and other services particularly, though not exclusively, ... “We have complementary strengths and a similar set of ...
(Date:4/24/2015)... 2015 Leading Regenerative Veterinary Medicine ... allogeneic stem-cell product development program and changes its’ ... corporate strategic direction. , “I am extremely pleased ... cell development program has been kicked into high ... facility and hiring of our new Director of ...
Breaking Biology Technology:BellBrook Labs Webinar: Analyzing Kinase Inhibitor Residence Times using the Transcreener® ADP Assay 25th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 25th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 3South Dakota Mines, Arizona State University Pave Way for Cooperative Research 2Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma 2
... DIEGO , May 11 Biomatrica, ... a solution-centric partnership program established with industry and ... storage and management of nucleic acids.  The Biomatrica ... for the development, testing, validation and use of ...
... May 11 Trans World Alloys (TWA) , one of the ... of their state-of-the-art, 40,000 square foot service center at 249 East Gardena Blvd., ... , (Photo: ... For the past ...
... Rice University researchers report using ultracentrifugation (UCF) to create ... team, led by Rice Professor Junichiro Kono and graduate ... small but significant step toward the dream of an ... quantum nanowire. The other, led by Rice Professor ...
Cached Biology Technology:Biomatrica Launches New Partnership Program - Biomatrica Connect(TM) 2Biomatrica Launches New Partnership Program - Biomatrica Connect(TM) 3Biomatrica Launches New Partnership Program - Biomatrica Connect(TM) 4Biomatrica Launches New Partnership Program - Biomatrica Connect(TM) 5Biomatrica Launches New Partnership Program - Biomatrica Connect(TM) 6Titanium and Aluminum Distributor, Trans World Alloys Relocates to Its Newly Built, State-of-the-Art Headquarters in Gardena, California 2Nano parfait a treat for scientists 2Nano parfait a treat for scientists 3
(Date:4/21/2015)... Canada , April 21, 2015 ... and evolving government policies are boosting access control systems ... According to a recently published report by ... Opportunities, 2020 ", the access control systems market in ... nearly USD1.2 billion by 2020.The access control systems market ...
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/20/2015)... The announcement comes as demand ... Management (GRM), Ireland,s foremost records management ... built up an impressive track record of clients within the ... the records management sector in Dubai . ... staffbase and employ a further eight staff members at its ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... Chemical Society (ACS) Weekly PressPac from the Office of ... journals and Chemical & Engineering News ., Please ... as the source for this information.` PressPac Archive: ... New tests: Marijuana damages DNA and may ...
... New Zealand researchers have accelerated research into Multiple Sclerosis ... help to unravel the causes of MS and other ... published today in the prestigious journal Nature Genetics ... remained a mystery. This discovery reveals important new insights ...
... Supply Chain Council -- Global Organization -- Begins in Houston ... and academic member, University of Houston ... College of Technology , ... first permanent Regional Center of Excellence for the U.S. Gulf Region. ...
Cached Biology News:American Chemical Society weekly presspac -- June 10, 2009 2American Chemical Society weekly presspac -- June 10, 2009 3American Chemical Society weekly presspac -- June 10, 2009 4American Chemical Society weekly presspac -- June 10, 2009 5American Chemical Society weekly presspac -- June 10, 2009 6American Chemical Society weekly presspac -- June 10, 2009 7Aussie and Kiwi researchers make double MS genetic discovery 2University of Houston Site of Regional Center of Excellence 2